[VIRTUAL] NRG Oncology / RTOG 1119: Phase II randomized study of whole brain radiotherapy / stereotactic radiosurgery with concurrent lapatinib in patients with brain metastases from HER2-positive breast cancer

[VIRTUAL] Delivery and activity of SN-38 by Sacituzumab Govitecan in CNS Tumors

[VIRTUAL] Maintenance chemotherapy using bevacizumab for neurofibromatosis 2 patients with hearing loss and progressive vestibular schwannomas: an NF Clinical Trials Consortium study (NF104)

[VIRTUAL] CODEL: Phase III trial of RT alone, RT plus TMZ, or TMZ alone for newly-diagnosed, 1p/19q codeleted anaplastic oligodendroglioma. Analysis from the initial study design.(NCCTG N0577, Alliance)

[VIRTUAL] Interim results of a phase I/IIa study to evaluate the safety and efficacy of BBB opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients prior to IV carboplatin

[VIRTUAL] Efficacy of ONC201 in patients with ONC201 for recurrent H3 K27M-mutant diffuse midline glioma

[VIRTUAL] Low-Risk Meningioma: Outcomes from NRG Oncology/RTOG 0539

[VIRTUAL] Combination of Controlled Interleukin-12 Gene Therapy with Immune Checkpoint Blockade in Recurrent Glioblastoma: Updated Results of a Multi-Institutional, Open Label Phase 1 Trial

[VIRTUAL] Randomized Phase 2 Study of Nivolumab (nivo) plus Either Standard or Reduced Dose Bevacizumab (bev) in Recurrent Glioblastoma (rGBM)

[VIRTUAL] Clinical efficacy of MDNA55, an interleukin-­4 receptor targeted immunotherapy, in recurrent GBM delivered by convection enhanced delivery (CED)

[VIRTUAL] Phase 2 Trial of Controlled IL-12 in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma (rGBM)

[VIRTUAL] Crucial application of single cell gene expression for monitoring changes in glioblastoma patients with sustained radiographic response to CMV pp65-LAMP RNA-pulsed dendritic cell-based vaccines

[VIRTUAL] Phase II and biomarker study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma patients

[VIRTUAL] CC-115 in newly diagnosed MGMT unmethylated glioblastoma in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II randomized Bayesian adaptive platform trial

[VIRTUAL] Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization.